Focus on thrombin: Alternative anticoagulants

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 4, 2007, Pages 256-260

  Merry, Alan F ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticoagulants; Bivalirudin; Blood loss; Cardiopulmonary bypass surgery; Heparin; HIT

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; DIPYRIDOMOLE; ECARIN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; ILOPROST; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; THROMBIN; THROMBIN INHIBITOR; TIROFIBAN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; HEART SURGERY; HEMODYNAMIC MONITORING; HUMAN; INFLAMMATION; LIVER FAILURE; NEPHROTIC SYNDROME; NONHUMAN; PREECLAMPSIA; SHOCK; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA;

ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PROTAMINES; RECOMBINANT PROTEINS; THROMBIN;

EID: 38849097771     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253207311154     Document Type: Conference Paper

References (40)

1. Gibbon JH, Jr. The development of the heart-lung apparatus. Am J Surg. 1978 ; 135: 608-619.
2. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg. 2004 ; 77: 925-931.
3. Charlesworth DC, Likosky DS, Marrin CA, Maloney CT, Quinton HB, Morton JR, et al. Development and validation of a prediction model for strokes after coronary artery bypass grafting. Ann Thorac Surg. 2003 ; 76: 436-443.
4. Engoren MC, Habib RH, Zacharias A., Schwann TA, Riordan CJ, Durham SJ Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002 ; 74: 1180-1186.
5. Spiess BD Heparin: beyond an anticoagulant. In: Spiess BD, ed. The relationship Between Coagulation, Inflammation, and Endothelium. Baltimore, MD: 2000: 169-190.
6. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003 ; 76: 638-648.
7. Williams RT, Damaraju LV, Mascelli MA, et al. Antiplatelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation. 2003 ; 107: 2307-2312.
8. Warkentin TE, Levine MN, Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995 ; 332: 1330-1335.
9. Pouplard C., May MA, Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999 ; 99: 2530-2536.
10. Mattioli AV, Bonetti L., Sternieri S., Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J. 2000 ; 1: 39-42.
11. Spiess BD Transfusion and outcome in heart surgery. Ann Thorac Surg. 2002 ; 74: 986-987.
12. Lemmer JH Jr, Despotis GJ Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2002 ; 123: 213-217.
13. Kimmel SE, Sekeres M., Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg. 2002 ; 94: 1402-1408.
14. Butterworth J., Lin YA, Prielipp RC, Bennett J., Hammon JW, James RL Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002 ; 74: 1589-1595.
15. Frederiksen JW Cardiopulmonary bypass in humans: bypassing unfractionated heparin. Ann Thorac Surg. 2000 ; 70: 1434-1443.
16. Weitz JI Low-molecular-weight heparins. N Engl J Med. 1997 ; 337: 688-698.
17. Doherty DC, Ortel TL, de Bruijn N., Greenberg CS, Van Trigt P. III. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology. 1990 ; 73: 562-565.
18. Illig KA, Ouriel K. Ancrod: understanding the agent. Semin Vasc Surg. 1996 ; 9: 303-314.
19. Brieger DB, Mak KH, Kottke-Marchant K., Topol EJ Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998 ; 31: 1449-1459.
20. Walls JT, Curtis JJ, Silver D., Boley TM, Schmaltz RA, Nawarawong N. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg. 1992 ; 53: 787-791.
21. Koster A., Kukucka M., Bach F., et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology. 2001 ; 94: 245-251.
22. Koster A., Meyer O., Fischer T., et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg. 2001 ; 122: 1254-1255.
23. Potzsch B., Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000 ; 343: 515.
24. Nowak G., Bucha E. Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thromb Res. 1995 ; 80: 317-325.
25. Koster A., Kuppe H., Hetzer R., Sodian R., Crystal GJ, Mertzlufft F. Emergent cardiopulmonary bypass in 5 patients with heparin-induced thrombocytopenia type II employing hirudin. Anesthesiology. 1998 ; 89: 777-780.
26. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002 ; 106: V275 - V284.
27. Lubenow N., Selleng S., Wollert HG, Eichler P., Mullejans B., Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg. 2003 ; 75: 577-579.
28. Edwards JT, Hamby JK, Worrall NK Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg. 2003 ; 75: 1622-1624.
29. Furukawa K., Ohteki H., Hirahara K., Narita Y., Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg. 2001 ; 122: 1255-1256.
30. Greinacher A., Lubenow N., Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Ciruclation. 2003 ; 108: 2062-2065.
31. Koster A., Chew D., Grundel M., Bauer M., Kuppe H., Spiess BD Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003 ; 96: 383-386.
32. Fox I., Dawson A., Loynds P., et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993 ; 69: 157-163.
33. Robson R., White H., Aylward P., Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002 ; 71: 433-439.
34. Antman EM Should bivalirudin replace heparin during percutaneous coronary interventions ? JAMA. 2003 ; 289: 903-905.
35. Smedira NG, Dyke CM, Koster A., et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006 ; 131: 686-692.
36. Dyke CM, Smedira NG, Koster A., et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006 ; 131: 533-539.
37. Koster A., Chew D., Grundel M., et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg. 2003 ; 96: 1316-1319.
38. Koster A., Spiess B., Jurmann M., et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLU-TION OFF" trial. Anesth Analg. 2006 ; 103: 540-544.
39. Koster A., Fischer T., Gruendel M., et al. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth. 2003 ; 17: 171-175.
40. Welsby IJ, Jones WL, Arepally G., et al. Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. Anesthesiology. 2007 ; 106: 295-301.